...Symphony ViDA, which was formed by private equity firm Symphony Capital. OxiGene out-licensed the compound to Symphony ViDA...

...OxiGene completed its previously announced acquisition of Symphony ViDA, which was formed by private equity firm Symphony...
...to account for the difference (see BioCentury, July 13). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....

...week, Achillion shed $0.28 (17%) to $1.40. Redeploying ViDA By exercising its option to acquire Symphony ViDA...
...of cash and avoid a further buyback obligation of some $15 million. Symphony Capital formed Symphony ViDA...
...million. Last week's acquisition will add about $12.5 million, which is the cash remaining in Symphony ViDA...

...OxiGene exercised its option to acquire Symphony ViDA in a stock deal. OxiGene gained the option last...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...

...OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN) exercised its option to acquire Symphony ViDA Inc. (Rockville, Md.) in a stock deal...
...when it out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 combretastatin A1 di-phosphate (CA1P) to Symphony ViDA...
...will increase its ownership of OxiGene's outstanding shares from 37% to 44%. OxiGene will get Symphony ViDA's...

...American Society of Clinical Oncology meeting in Orlando. Last October, OxiGene out-licensed the compound to Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....

...carcinoma (HCC) or secondary hepatic tumor involvement. Last October, OxiGene out-licensed the compound to newco Symphony ViDA...
...option to acquire Symphony ViDA (see BioCentury, Oct. 6, 2008). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. Symphony ViDA Inc....

...million in cash. Symphony gained the warrant in its October deal with OxiGene to form Symphony ViDA Inc....

...was valued at last Tuesday, the day before the deal was announced. The newco, called Symphony ViDA...

...OxiGene out-licensed Zybrestat fosbretabulin for ophthalmic indications and cancer compound OXi4503 to newco Symphony ViDA Inc. Symphony ViDA was...
...received an exclusive option to acquire Symphony ViDA. If the company does not exercise its option, Symphony ViDA...
...receive up to $1 million in OxiGene stock upon additional investment by Symphony Capital in Symphony ViDA...